KRASG12D, pulmonary LCH, and atorvastatin

被引：1

作者：

Aouba, Achille ^{[1
]}

机构：

[1] Univ Caen Normandy, Caen, France

来源：

BLOOD | 2017年 / 130卷 / 04期

关键词：

LANGERHANS CELL HISTIOCYTOSIS; MUTATIONS;

D O I：

10.1182/blood-2017-06-788455

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In this issue of Blood, Kamata et al(1) elegantly demonstrate in mice that (1) KRAS(G12D) (but not BRAF(V600E)) mutation transfection in pulmonary myeloid cells induces an isolated pulmonary (IP)-Langerhans cell histiocytosis (LCH)-like neoplasm, via phosphatidylinositol 3-kinase (PI3K) activation, and that (2) atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A inhibitor that inhibits RAS interaction of PI3K, reduces tumor burden in vivo.

引用

页码：391 / 392

页数：4

共 50 条

[31] Targeting the "Undruggable" Driver Protein, KRASG12D, as Potential Therapy in Prostate Cancer
Kargbo, Robert B.
ACS MEDICINAL CHEMISTRY LETTERS, 2023, 14 (04): : 365 - 366
[32] Angiogenic Property of Mouse Pancreatic Cancer Cells From KrasG12D/p53-/- and KrasG12D/Smad4-/- Transgenic Mice, and Differential Effect of Triptolide on the Tumor Angiogenesis
Yokoyama, Y.
Vickers, S. M.
Saluja, A. K.
PANCREAS, 2009, 38 (08) : 1065 - 1065
[33] Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor
Wang, Xiaolun
Allen, Shelley
Blake, James F.
Bowcut, Vickie
Briere, David M.
Calinisan, Andrew
Dahlke, Joshua R.
Fell, Jay B.
Fischer, John P.
Gunn, Robin J.
Hallin, Jill
Laguer, Jade
Lawson, J. David
Medwid, James
Newhouse, Brad
Phong Nguyen
O'Leary, Jacob M.
Olson, Peter
Pajk, Spencer
Rahbaek, Lisa
Rodriguez, Mareli
Smith, Christopher R.
Tang, Tony P.
Thomas, Nicole C.
Vanderpool, Darin
Vigers, Guy P.
Christensen, James G.
Marx, Matthew A.
JOURNAL OF MEDICINAL CHEMISTRY, 2021, : 3123 - 3133
[34] KrasG12D and p53 Mutation Cause Primary intrahepatic Cholangiocarcinoma
O'Dell, Michael R.
Huang, Jing Li
Whitney-Miller, Christa L.
Deshpande, Vikram
Rothberg, Paul
Grose, Valerie
Rossi, Randall M.
Zhu, Andrew X.
Land, Hartmut
Bardeesy, Nabeel
Hezel, Aram F.
CANCER RESEARCH, 2012, 72 (06) : 1557 - 1567
[35] On the impact of KRASG12D subtype non-small cell lung cancer
Lopez, Sandra
CLINICAL & TRANSLATIONAL ONCOLOGY, 2024,
[36] RMC-9805, a first-in-class, mutant-selective, covalent and oral KRASG12D(ON) inhibitor that induces apoptosis and drives tumor regression in preclinical models of KRASG12D cancers
Jiang, Lingyan
Menard, Marie
Weller, Caroline
Wang, Zhican
Burnett, Les
Aronchik, Ida
Steele, Shelby
Flagella, Mike
Zhao, Ruiping
Evans, James W. W.
Chin, Shook
Chou, Kang-Jye
Mu, Yunming
Longhi, Michael
McDowell, Laura
Knox, John E.
Gill, Adrian
Smith, Jacqueline A.
Singh, Mallika
Quintana, Elsa
Jiang, Jingjing
CANCER RESEARCH, 2023, 83 (07)
[37] Effects of KRASG12D and P53 oncogenes on pancreatic cellular plasticity
Chen, Jeff
Contino, Gianmarco
Gurumurthy, Sushma
Bardeesy, Nabeel
CANCER RESEARCH, 2011, 71
[38] Discovery and characterization of a high orally available small molecule inhibitor of KRASG12D
Zhang, Y.
Feng, Z.
Huang, X.
Sun, M.
Yang, F.
Yu, H.
Chen, Z.
Ying, H.
EUROPEAN JOURNAL OF CANCER, 2024, 211 : S17 - S17
[39] KRASG12D inhibition in pancreatic cancer: Fas expression facilitates immune clearance
Yeh, Celine
Park, Wungki
Yaeger, Rona
DEVELOPMENTAL CELL, 2023, 58 (17) : 1515 - 1516
[40] MGST1 facilitates novel KRASG12D inhibitor resistance in KRASG12D-mutated pancreatic ductal adenocarcinoma by inhibiting ferroptosis
Xu, Chungui
Lin, Weihao
Zhang, Qi
Ma, Yarui
Wang, Xue
Guo, Ai
Zhu, Guiling
Zhou, Zhendiao
Song, Weiwei
Zhao, Ziyi
Jiao, Yuchen
Wang, Xiaobing
Du, Chunxia
MOLECULAR MEDICINE, 2024, 30 (01)

← 1 2 3 4 5 →